BioNTech SE (BNTX) Receivables (2018 - 2025)
BioNTech SE (BNTX) posted Receivables of $11.8 million for Q4 2025, down 98.54% sequentially from $807.6 million in Q3 2025, and down 44.43% YoY from $21.2 million in Q4 2024.
BioNTech SE (BNTX) Receivables (2018 - 2025) Analysis & Trends
BioNTech SE has reported Receivables for 8 years, with the latest figure at $11.8 million in Q4 2025.
- Quarterly Receivables fell 44.43% year-over-year to $11.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $11.8 million (down 44.43% YoY) and the FY2025 annual result came in at $1.0 billion, down 33.25% from the prior year.
- Receivables fell to $11.8 million in Q4 2025 per BNTX's latest filing, from $807.6 million in the prior quarter.
- Over five years, Receivables peaked at $14.2 billion in Q1 2022 and troughed at $5.3 million in Q4 2023.
- A 5-year average of $4.0 billion and a median of $1.8 billion in 2024 frame the typical range for Receivables.
- The sharpest annual moves came in 2021 and 2024: Receivables surged 7078.2% in 2021, then slumped 97.18% in 2024.
- Over 5 years, Receivables stood at $14.2 billion in 2021, then sank by 47.97% to $7.4 billion in 2022, then sank by 99.93% to $5.3 million in 2023, then jumped by 301.32% to $21.2 million in 2024, then slumped by 44.43% to $11.8 million in 2025.
- According to Business Quant data, Receivables over the past three periods registered $11.8 million, $807.6 million, and $1.5 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.93 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.06 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.84 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 912.74 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 215.33 Mn |
| 10 | BioNTech SE | 23.54 Bn | 5.15 Bn | 668.28 Mn | 1.09 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.08 Bn |
| Sep 30, 2025 | 807.58 Mn |
| Jun 30, 2025 | 1.55 Bn |
| Mar 31, 2025 | 1.01 Bn |
| Dec 31, 2024 | 1.56 Bn |
| Sep 30, 2024 | 1.09 Bn |
| Jun 30, 2024 | 81.63 Mn |
| Mar 31, 2024 | 1.78 Bn |
| Dec 31, 2023 | 2.32 Bn |
| Sep 30, 2023 | 2.18 Bn |
| Jun 30, 2023 | 2.89 Bn |
| Mar 31, 2023 | 6.92 Bn |
| Sep 30, 2022 | 7.37 Bn |
| Jun 30, 2022 | 11.08 Bn |
| Mar 31, 2022 | 14.25 Bn |
| Dec 31, 2021 | 14.16 Bn |
| Mar 31, 2021 | 2.89 Bn |
| Dec 31, 2020 | 197.32 Mn |
| Dec 31, 2019 | 13.19 Mn |
| Sep 30, 2019 | 9.94 Mn |